



(11) **EP 3 135 692 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 5/10 (2006.01) **C12N 15/09** (2006.01)
C12N 15/62 (2006.01) **C12N 15/82** (2006.01)
C12N 15/86 (2006.01) **A61K 47/68** (2017.01)
C07K 16/18 (2006.01) **C07K 16/30** (2006.01)
G01N 33/574 (2006.01) **A61K 39/00** (2006.01)
G01N 33/577 (2006.01)

(48) Corrigendum issued on:
20.03.2019 Bulletin 2019/12

(45) Date of publication and mention
of the grant of the patent:
01.08.2018 Bulletin 2018/31

(21) Application number: **16187573.7**

(22) Date of filing: **15.06.2011**

(54) **ANTIBODIES TO ENDOPLASMIN AND THEIR USE**

ANTIKÖRPER ZU ENDOPLASMIN UND DEREN VERWENDUNG

ANTICORPS DIRIGÉS CONTRE L'ENDOPLASMINE ET LEUR UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **16.06.2010 US 355516 P**

(43) Date of publication of application:
01.03.2017 Bulletin 2017/09

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
11796394.2 / 2 582 727

(73) Proprietor: **University of Pittsburgh - Of the**
Commonwealth
System of Higher Education
Pittsburgh, PA 15260 (US)

(72) Inventors:
• **FERRONE, Soldano**
Boston, MA 02108 (US)

- **WANG, Xinhui**
Boston, MA 02135 (US)
- **CONRADS, Thomas P.**
Reston, VA 20191 (US)
- **FAVOINO, Elvira**
Casamassima BA 70010 (IT)
- **HOOD, Brian**
Reston, VA 20191 (US)

(74) Representative: **Gowshall, Jonathan Vallance**
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München (DE)

(56) References cited:
WO-A1-2009/039409 **WO-A1-2009/113074**
WO-A1-2012/075324 **WO-A2-2006/120230**
US-A1- 2004 001 789 **US-A1- 2005 008 649**

EP 3 135 692 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).